Rocket Pharmaceuticals Current Ratio Growth & History (RCKT)
Rocket Pharmaceuticals's current ratio was 6.38 for fiscal 2025.
View full Rocket Pharmaceuticals company overviewRocket Pharmaceuticals annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 6.38 | −2.91 | −31.36% |
| 2024 | 2024-12-31 | 9.30 | 1.50 | +19.21% |
| 2023 | 2023-12-31 | 7.80 | −1.50 | −16.11% |
| 2022 | 2022-12-31 | 9.29 | −8.39 | −47.45% |
| 2021 | 2021-12-31 | 17.69 | 2.75 | +18.37% |
| 2020 | 2020-12-31 | 14.94 | −1.87 | −11.11% |
| 2019 | 2019-12-31 | 16.81 | 3.21 | +23.58% |
| 2018 | 2018-12-31 | 13.60 | 9.41 | +224.42% |
| 2017 | 2017-12-31 | 4.19 | −14.03 | −77.00% |
| 2016 | 2016-12-31 | 18.23 | −8.91 | −32.83% |
| 2015 | 2015-12-31 | 27.13 | 26.63 | +5239.75% |
| 2014 | 2014-12-31 | 0.51 | — | — |
Rocket Pharmaceuticals quarterly current ratio
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 9.24 | 2.86 | +44.76% |
| Q1 2026 | 2026-03-31 | 6.12 | −3.07 | −33.36% |
| Q4 2025 | 2025-12-31 | 6.38 | −2.91 | −31.36% |
| Q3 2025 | 2025-09-30 | 7.30 | 1.26 | +20.80% |
| Q2 2025 | 2025-06-30 | 6.39 | −1.40 | −17.99% |
| Q1 2025 | 2025-03-31 | 9.19 | −1.28 | −12.25% |
| Q4 2024 | 2024-12-31 | 9.30 | 1.50 | +19.21% |
| Q3 2024 | 2024-09-30 | 6.05 | −7.30 | −54.70% |
| Q2 2024 | 2024-06-30 | 7.79 | −1.30 | −14.30% |
| Q1 2024 | 2024-03-31 | 10.47 | −0.36 | −3.32% |
| Q4 2023 | 2023-12-31 | 7.80 | −1.50 | −16.11% |
| Q3 2023 | 2023-09-30 | 13.35 | 3.04 | +29.49% |
| Q2 2023 | 2023-06-30 | 9.09 | −4.33 | −32.25% |
| Q1 2023 | 2023-03-31 | 10.83 | −4.85 | −30.91% |
| Q4 2022 | 2022-12-31 | 9.29 | −8.39 | −47.45% |
| Q3 2022 | 2022-09-30 | 10.31 | −7.05 | −40.61% |
| Q2 2022 | 2022-06-30 | 13.41 | −3.50 | −20.72% |
| Q1 2022 | 2022-03-31 | 15.68 | 4.03 | +34.55% |
| Q4 2021 | 2021-12-31 | 17.69 | 2.75 | +18.37% |
| Q3 2021 | 2021-09-30 | 17.36 | 10.06 | +137.83% |
| Q2 2021 | 2021-06-30 | 16.92 | 4.57 | +36.99% |
| Q1 2021 | 2021-03-31 | 11.65 | −1.60 | −12.07% |
| Q4 2020 | 2020-12-31 | 14.94 | −1.87 | −11.11% |
| Q3 2020 | 2020-09-30 | 7.30 | −3.77 | −34.08% |
| Q2 2020 | 2020-06-30 | 12.35 | −5.13 | −29.36% |
| Q1 2020 | 2020-03-31 | 13.25 | 3.55 | +36.57% |
| Q4 2019 | 2019-12-31 | 16.81 | 3.21 | +23.58% |
| Q3 2019 | 2019-09-30 | 11.07 | −1.44 | −11.52% |
| Q2 2019 | 2019-06-30 | 17.48 | 4.21 | +31.76% |
| Q1 2019 | 2019-03-31 | 9.70 | −15.49 | −61.48% |
| Q4 2018 | 2018-12-31 | 13.60 | 9.41 | +224.42% |
| Q3 2018 | 2018-09-30 | 12.51 | −15.06 | −54.62% |
| Q2 2018 | 2018-06-30 | 13.27 | −14.08 | −51.48% |
| Q1 2018 | 2018-03-31 | 25.19 | 3.05 | +13.78% |
| Q4 2017 | 2017-12-31 | 4.19 | −14.03 | −77.00% |
| Q3 2017 | 2017-09-30 | 27.57 | 4.20 | +17.98% |
| Q2 2017 | 2017-06-30 | 27.35 | 3.10 | +12.79% |
| Q1 2017 | 2017-03-31 | 22.14 | −0.24 | −1.06% |
| Q4 2016 | 2016-12-31 | 18.23 | −8.91 | −32.83% |
| Q3 2016 | 2016-09-30 | 23.37 | −13.39 | −36.43% |
| Q2 2016 | 2016-06-30 | 24.25 | 4.07 | +20.16% |
| Q1 2016 | 2016-03-31 | 22.38 | 0.63 | +2.88% |
| Q4 2015 | 2015-12-31 | 27.13 | 26.63 | +5239.75% |
| Q3 2015 | 2015-09-30 | 36.76 | — | — |
| Q2 2015 | 2015-06-30 | 20.18 | — | — |
| Q1 2015 | 2015-03-31 | 21.75 | — | — |
| Q4 2014 | 2014-12-31 | 0.51 | — | — |
Rocket Pharmaceuticals current ratio trends
Over the last five fiscal years, Rocket Pharmaceuticals's current ratio decreased from 14.94 to 6.38, a change of −8.56. The latest reported quarter, Q2 2026, shows 9.24.
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Rocket Pharmaceuticals source filings ↗